Search Results - "Colomer Pujol, Dolors"

Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia by Giménez, Neus, Martínez-Trillos, Alejandra, Montraveta, Arnau, Lopez-Guerra, Mónica, Rosich, Laia, Nadeu, Ferran, Valero, Juan G, Aymerich, Marta, Magnano, Laura, Rozman, Maria, Matutes, Estella, Delgado, Julio, Baumann, Tycho, Gine, Eva, González, Marcos, Alcoceba, Miguel, Terol, M José, Navarro, Blanca, Colado, Enrique, Payer, Angel R, Puente, Xose S, López-Otín, Carlos, Lopez-Guillermo, Armando, Campo, Elias, Colomer, Dolors, Villamor, Neus

“…Mutations in genes of the RAS-BRAF-MAPK-ERK pathway have not been fully explored in patients with chronic lymphocytic leukemia. We, therefore, analyzed the…”
Get full text

The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia by Xargay-Torrent, Sílvia, López-Guerra, Mónica, Rosich, Laia, Montraveta, Arnau, Roldán, Jocabed, Rodríguez, Vanina, Villamor, Neus, Aymerich, Marta, Lagisetti, Chandraiah, Webb, Thomas R, López-Otín, Carlos, Campo, Elias, Colomer, Dolors

“…Mutations or deregulated expression of the components of the spliceosome can influence the splicing pattern of several genes and contribute to the development…”
Get full text

Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy by Silkenstedt, Elisabeth, Arenas, Fabian, Colom-Sanmartí, Berta, Xargay-Torrent, Sílvia, Higashi, Morihiro, Giró, Ariadna, Rodriguez, Vanina, Fuentes, Patricia, Aulitzky, Walter E, van der Kuip, Heiko, Beà, Sílvia, Toribio, Maria L, Campo, Elias, López-Guerra, Mònica, Colomer, Dolors

“…NOTCH1 gene mutations in mantle cell lymphoma (MCL) have been described in about 5-10% of cases and are associated with significantly shorter survival rates…”
Get full text

Impact of the functional CD5 polymorphism A471V on the response of chronic lymphocytic leukaemia to conventional chemotherapy regimens by Delgado, Julio, Bielig, Torsten, Bonet, Lizette, Carnero‐Montoro, Elena, Puente, Xose S., Colomer, Dolors, Bosch, Elena, Campo, Elias, Lozano, Francisco

“…Chronic lymphocytic leukaemia (CLL) represents an abnormal clonal expansion of mature antigen-experienced CD5+ B1a cells (Chiorazzi et al, 2005), which present…”
Get full text

Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma by Recasens-Zorzo, Clara, Cardesa-Salzmann, Teresa, Petazzi, Paolo, Ros-Blanco, Laia, Esteve-Arenys, Anna, Clot, Guillem, Guerrero-Hernández, Martina, Rodríguez, Vanina, Soldini, Davide, Valera, Alexandra, Moros, Alexandra, Climent, Fina, González-Barca, Eva, Mercadal, Santiago, Arenillas, Leonor, Calvo, Xavier, Mate, José Luís, Gutiérrez-García, Gonzalo, Casanova, Isolda, Mangues, Ramón, Sanjuan-Pla, Alejandra, Bueno, Clara, Menéndez, Pablo, Martínez, Antonio, Colomer, Dolors, Tejedor, Roger Estrada, Teixidó, Jordi, Campo, Elias, López-Guillermo, Armando, Borrell, José Ignacio, Colomo, Luis, Pérez-Galán, Patricia, Roué, Gaël

“…Constitutive activation of the chemokine receptor CXCR4 has been associated with tumor progression, invasion, and chemotherapy resistance in different cancer…”
Get full text

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens by Vidal Crespo, Anna, Matas Céspedes, Alba, Rodríguez, Vanina, Rossi, Cédric, Valero, Juan G, Serrat, Neus, Sanjuan Pla, Alejandra, Menéndez, Pablo, Roué, Gaël, López-Guillermo, A, Giné Soca, Eva, Campo Güerri, Elias, Colomer Pujol, Dolors, Bezombes, Christine, Lammerts van Bueren, J, Chiu, Christopher, Doshi, Parul, Pérez-Galán, Patricia

“…CD38 is expressed in several types of non-Hodgkin lymphoma and constitutes a promising target for antibody-based therapy. Daratumumab (Darzalex) is a…”
Get full text

Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma by Recasens Zorzo, Clara, Cardesa Salzmann, Teresa, Petazzi, Paolo, Ros Blanco, Laia, Esteve Arenys, Anna, Clot, Guillem, Guerrero Hernández, Martina, Rodríguez, Vanina, Soldini, Davide, Valera Barros, Alexandra, Moros Sanz, Alexandra, Climent, Fina, González Barca, Eva, Mercadal, Santiago, Arenillas Rocha, Leonor, Calvo, Xavier, Mate, José L, Gutiérrez García, Gonzalo, Casanova Rigat, Isolda, Mangues Bafalluy, Ramon, Sanjuan Pla, Alejandra, Bueno, Clara, Menéndez, Pablo, Martínez, Antonio, Colomer Pujol, Dolors, Estrada Tejedor, Roger, Teixidó, Jordi, Campo Güerri, Elias, López Guillermo, Armando, Borrell, José I, Colomo Saperas, Lluís, Pérez Galán, Patricia, Roué, Gaël

“…Constitutive activation of the chemokine receptor CXCR4 has been associated with tumor progression, invasion, and chemotherapy resistance in different cancer…”
Get full text

Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption by Delgado, Julio, Salaverria, Itziar, Baumann, Tycho, Martínez-Trillos, Alejandra, Lee, Eriong, Jiménez, Laura, Navarro, Alba, Royo, Cristina, Santacruz, Rodrigo, López, Cristina, Payer, Angel R, Colado, Enrique, González, Marcos, Armengol, Lluís, Colomer, Dolors, Pinyol, Magda, Villamor, Neus, Aymerich, Marta, Carrió, Ana, Costa, Dolors, Clot, Guillem, Giné, Eva, López-Guillermo, Armando, Campo, Elías, Beà, Sílvia

“…The clinical course of chronic lymphocytic leukemia (CLL) is extremely heterogeneous and while some patients achieve a normal lifespan, others succumb to the…”
Get full text

The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy by Santacruz, Rodrigo, Villamor, Neus, Aymerich, Marta, Martínez-Trillos, Alejandra, López, Cristina, Navarro, Alba, Rozman, María, Beà, Sílvia, Royo, Cristina, Cazorla, Maite, Colomer, Dolors, Giné, Eva, Pinyol, Magda, Puente, Xose S, López-Otín, Carlos, Campo, Elías, López-Guillermo, Armando, Delgado, Julio

“…A proportion of patients with chronic lymphocytic leukemia achieve a minimal residual disease negative status after therapy. We retrospectively evaluated the…”
Get full text

CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia by Montraveta, Arnau, Lee-Vergés, Eriong, Roldán, Jocabed, Jiménez, Laura, Cabezas, Sandra, Clot, Guillem, Pinyol, Magda, Xargay-Torrent, Sílvia, Rosich, Laia, Arimany-Nardí, Cristina, Aymerich, Marta, Villamor, Neus, López-Guillermo, Armando, Pérez-Galán, Patricia, Roué, Gaël, Pastor-Anglada, Marçal, Campo, Elías, López-Guerra, Mónica, Colomer, Dolors

“…Clinical responses to bendamustine in chronic lymphocytic leukemia (CLL) are highly heterogeneous and no specific markers to predict sensitivity to this drug…”
Get full text

Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma by Rosich, Laia, Montraveta, Arnau, Xargay-Torrent, Sílvia, López-Guerra, Mónica, Roldán, Jocabed, Aymerich, Marta, Salaverria, Itziar, Beà, Sílvia, Campo, Elías, Pérez-Galán, Patricia, Roué, Gaël, Colomer, Dolors

“…Phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway activation contributes to mantle cell lymphoma (MCL) pathogenesis and…”
Get full text

Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma by Montraveta, Arnau, Xargay i Torrent, Sílvia, López Guerra, Mónica, Rosich, Laia, Pérez-Galán, Patricia, Salaverria Frigola, Itziar, Beà Bobet, Sílvia M, Kalko, Susana, Frias, Mercè de, Campàs, Clara, Roué, Gaël, Colomer Pujol, Dolors

“…Mantle cell lymphoma (MCL) is considered one of the most challenging lymphoma, with limited responses to current therapies. Acadesine, a nucleoside analogue…”
Get full text

Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia by Ferreira, Pedro G, Jares Gerboles, Pedro, Rico, Daniel, Gómez-López, Gonzalo, Martínez-Trillos, Alejandra, Villamor, Neus, Ecker, Simone, González-Pérez, Abel, Knowles, David G, Monlong, Jean, Johnson, Rory, Quesada, Victor, Djebali, Sarah, Papasaikas, Panagiotis, López-Guerra, Mónica, Colomer Pujol, Dolors, Royo, Cristina, Cazorla, Maite, Pinyol, Magda, Clot, Guillem, Aymerich Gregorio, Marta, Rozman, María, Kulis, Marta, Tamborero, David, Gouin, Anaïs, Blanc, Julie, Gut, Marta, Gut, Ivo, Puente, Xose S, Pisano, David G, Martín-Subero, José Ignacio, López-Bigas, Núria, López Guillermo, Armando, Valencia, Alfonso, López-Otín, Carlos, Campo Güerri, Elias, Guigó Serra, Roderic

“…Chronic lymphocytic leukemia (CLL) has heterogeneous clinical and biological behavior. Whole-genome and -exome sequencing has contributed to the…”
Get full text